ERBB2 and breast cancer: Taken together, our data imply that ctDNA is a valuable approach to detect genetic alterations related to trastuzumab resistance in BC patients, with mutations in DNA damage response pathway and/or PI3K pathway being found in both AR and IR patients while mutations in HER2 or other RTK/RAS pathway‐related genes being observed more in AR patients.